文献速递慢病防控与筛查卫生政策与健康促进

1990-2021年日本人口健康变化三十年:2021年全球疾病负担研究的次国家分析

Three decades of population health changes in Japan, 1990-2021: a subnational analysis for the Global Burden of Disease Study 2021.
PubMed 文献 · Lancet Public Health · 2025-03-20

该研究基于2021年全球疾病负担研究(GBD),利用日本1474个数据源、371种疾病和88种风险因素,评估1990-2021年日本国家及次国家层面的人口健康变化。研究发现日本预期寿命从79.4岁升至85.2岁,但都道府县间差异扩大,健康改善速度放缓,阿尔茨海默病及其他痴呆、糖尿病及高空腹血糖和高BMI负担上升。

要点

  • 1990-2021年日本预期寿命从79.4岁升至85.2岁,但都道府县间差异扩大。
  • 2021年主要死因包括阿尔茨海默病及其他痴呆、卒中、缺血性心脏病和肺癌。
  • 糖尿病年龄标化DALY率恶化,年化变化率从2005-15年的0.1%升至2015-21年的2.2%。

核心结论

  • 日本过去30年的健康增益正在停滞,地区差异上升。
  • 阿尔茨海默病及其他痴呆和糖尿病负担增加,同时高空腹血糖和高BMI问题突出,是需要重点关注和行动的领域。

研究设计与样本

  • 基于2021年全球疾病负担研究(GBD),使用日本1474个数据源,覆盖371种疾病(包括COVID-19)和88种风险因素。
  • 采用标准化GBD方法,通过统计建模整合数据,包括死因集合模型、贝叶斯元回归疾病模型和风险因素估计框架。
  • 计算了1990-2005年、2005-15年和2015-21年按死因分解的预期寿命以及年龄标化死亡率和DALY的年化变化率。

主要发现

  • 1990年至2021年,日本预期寿命从79.4岁(95%不确定性区间79.3-79.4)升至85.2岁(85.1-85.2),都道府县间差异扩大。
  • 预期寿命增益主要归因于卒中死亡率下降(增加1.5年)、缺血性心脏病(1.0年)和肿瘤尤其是胃癌(0.5年),各都道府县间存在差异。
  • 2021年主要死因:阿尔茨海默病及其他痴呆每10万人口135.3例死亡(39.5-312.3),卒中114.9例(89.8-129.3),缺血性心脏病96.5例(77.7-106.7),肺癌72.1例(61.8-77.5)。
  • 全因死亡率年化变化率从2005-15年的-1.6%降至2015-21年的-1.1%。
  • 年龄标化COVID-19死亡率2020年为每10万人口0.8例死亡(0.7-0.9,占全部死亡的0.3%),2021年为3.0例(2.5-3.7,占死亡的1.0%)。

关键数值与推荐

  • 糖尿病年龄标化DALY率恶化,年化变化率从2005-15年的0.1%升至2015-21年的2.2%。
  • 高空腹血糖归因DALY年化变化率2005-15年为-0.8%,2015-21年为0.8%。
  • 高BMI归因DALY年化变化率2005-15年为0.2%,2015-21年为1.4%。
  • 其他主要风险因素归因的年龄标化DALY持续下降,但速度减慢。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Given Japan's rapidly ageing demographic structure, comprehensive and long-term evaluations of its national and subnational health progress are important to inform public health policy. This study aims to assess Japan's population health, using the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2021 to analyse the country's evolving disease patterns. METHODS: GBD 2021 used Japanese data from 1474 sources, covering 371 diseases, including COVID-19, and 88 risk factors. The analysis included estimates of life expectancy, mortality, and disability-adjusted life-years (DALYs). Estimates were generated using the standardised GBD methodology, which incorporates various data sources through statistical modelling, including the Cause Of Death Ensemble Model for mortality, Bayesian Meta-Regression Disease Model for non-fatal outcomes, and risk factor estimation frameworks to quantify attributable burdens. Life expectancy decomposition by cause of death and annualised rates of change of age-standardised mortality and DALYs were calculated for 1990-2005, 2005-15, and 2015-21. FINDINGS: Between 1990 and 2021, life expectancy in Japan rose from 79·4 years (95% uncertainty interval 79·3-79·4) to 85·2 years (85·1-85·2), with prefecture-level disparities widening. Gains were primarily driven by reduced mortality from stroke (adding 1·5 years to life expectancy), ischaemic heart disease (1·0 years), and neoplasms, particularly stomach cancer (0·5 years), with variation across prefectures. Leading causes of death in 2021 were Alzheimer's disease and other dementias (135·3 deaths [39·5-312·3] per 100 000 population), stroke (114·9 [89·8-129·3] per 100 000), ischaemic heart disease (96·5 [77·7-106·7] per 100 000), and lung cancer (72·1 [61·8-77·5] per 100 000). Age-standardised mortality for major non-communicable diseases declined, but the pace of this decline has slowed. All-cause annualised rate of change in mortality rate decreased from -1·6% for 2005-15 to -1·1% for 2015-21. Age-standardised COVID-19 mortality rates were 0·8 deaths (0·7-0·9) per 100 000 population (accounting for 0·3% of all deaths) in 2020 and 3·0 (2·5-3·7) per 100 000 population in 2021 (1·0% of deaths). Age-standardised DALY rates for diabetes worsened, with annualised rate of change increasing from 0·1% for 2005-15 to 2·2% for 2015-21. This change parallels worsening trends in major risk factors, particularly high fasting plasma glucose (annualised rate of change of attributable DALYs -0·8% for 2005-15 and 0·8% for 2015-21) and high BMI (0·2% and 1·4%, respectively). Age-standardised DALYs attributable to other major risk factors continued to decrease, albeit slower. INTERPRETATION: Japan's health gains over the past 30 years are now stalling, with rising regional disparities. The increasing burdens of Alzheimer's disease and other dementias and diabetes, alongside high fasting plasma glucose and high BMI, highlight areas needing focused attention and action. FUNDING: Gates Foundation.

来源:Lancet Public Health,查看原文。版权归原作者所有。

引用

  1. Three decades of population health changes in Japan, 1990-2021: a subnational analysis for the Global Burden of Disease Study 2021. Lancet Public Health. 2025. PMID: 40122087. doi:10.1016/S2468-2667(25)00044-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。